Ning Zhang | Molecular biotechnology | Best Researcher Award

Published on by Biotechnology Scientist

Assoc. Prof. Dr. Ning Zhang | Molecular Biotechnology | Best Researcher Award

Associate Professor at Liaocheng university | China

Assoc. Prof. Dr. Ning Zhang, a distinguished neuroscientist of Mongolian ethnicity, is a member of the Communist Party and currently focuses her research on neuroinflammatory immunity and myelin regeneration. She earned her doctoral degree in Neuroscience from Tierärztliche Hochschule Hannover, Germany, in November 2015. Dr. Zhang’s research primarily investigates the regulatory mechanisms of neuroinflammation and immune responses in neurodegenerative diseases, emphasizing the processes of remyelination and neuronal repair. Her studies further explore the intricate interactions among glial cells in the central nervous system during both development and disease progression. She is also deeply engaged in identifying novel therapeutic targets for neurodegenerative conditions and developing bioactive interventions aimed at mitigating neuronal damage. Dr. Zhang has made substantial contributions to the field through her publications and scientific discoveries, advancing understanding of cellular and molecular mechanisms underlying neural repair. Her work bridges fundamental neuroscience with translational approaches to improve clinical outcomes in neurodegenerative disorders. According to her Scopus profile, Dr. Zhang has authored 62 scientific documents, which have collectively garnered 868 citations across 667 publications, reflecting a significant impact in the global neuroscience community. She maintains an h-index of 19, demonstrating both the depth and influence of her research contributions in neuroinflammatory and regenerative neuroscience.

Profile: Scopus

Featured Publications

Zhang, N., et al. (2025). Ketogenic diet attenuates microglia-mediated neuroinflammation by inhibiting NLRP3 inflammasome activation via HDAC3 inhibition to activate mitophagy in experimental autoimmune encephalomyelitis. Food & Function. 3 citations

Zhang, N., et al. (2025). Exogenous ketogenic supplements can mitigate the susceptibility to Alzheimer’s disease induced by chronic sleep deprivation: Emerging role of Sirt1 in ferroptosis. Food Science and Human Wellness. 0 citations

Zhang, N., et al. (2025). Cetirizine platinum(IV) complexes with antihistamine properties inhibit tumor metastasis by suppressing angiogenesis and boosting immunity. Journal of Inorganic Biochemistry. 3 citations

Zhang, N., et al. (2024). Dynamic effects of ketogenic diet on autophagy and cell cycle in a mouse model of CT26+ colon cancer. Pakistan Journal of Zoology. 0 citations

Zhang, N., et al. (2024). Phase separation investigation of Axitinib in supersaturated solution. Crystals. 0 citations

Manish Kohli | Molecular Diagnostics | Excellence in Research Award

Published on by Biotechnology Scientist

Prof. Dr. Manish Kohli | Molecular Diagnostics | Excellence in Research Award

Director at University of Utah-Huntsman Cancer Institute | United States

Dr. Manish Kohli is a distinguished physician-scientist and academician whose career spans over two decades, focusing on transforming cancer care through convergence science and translational oncology. He currently serves as a tenured professor in the Department of Medicine at the University of Utah and holds the Jack and Hazel Robertson Presidential Endowed Chair in Cancer Research at the Huntsman Cancer Institute. Known for integrating clinical insight with computational approaches, Dr. Kohli leads multi-disciplinary research to develop personalized treatment strategies, particularly in prostate cancer. He is also the Director of the Physician Scientist Training Program, where he mentors emerging physician-researchers in internal medicine.

Profile

Scopus

Orcid

Education

Dr. Kohli received his M.B.B.S. from Maulana Azad Medical College, University of Delhi, followed by a residency in internal medicine at Cook County Hospital in Chicago. He completed his hematology and oncology fellowship training at the University of Arkansas for Medical Sciences. To enhance his skills in clinical research and data science, he pursued advanced training through certificate programs at Harvard Medical School, focusing on clinical trials and artificial intelligence in healthcare. His educational foundation reflects a seamless blend of clinical proficiency and data-driven research expertise.

Experience

Dr. Kohli has held academic and clinical leadership roles at several renowned institutions, including Mayo Clinic, H. Lee Moffitt Cancer Center, University of Rochester, and the University of Illinois at Urbana-Champaign. He served as Vice-Chair in the Department of Genitourinary Oncology and Director of Personalized Medicine at Moffitt Cancer Center. At Mayo Clinic, he was Professor of Oncology and a consultant in both medical oncology and urology. His administrative experience includes directing fellowship programs, co-chairing disease-specific working groups, serving on IRBs, and contributing to molecular pathology committees. His current role at the University of Utah includes active involvement in faculty advisory and innovation committees, shaping strategic research and training agendas.

Research interest

Dr. Kohli’s research lies at the intersection of cancer biology, bioengineering, and computational sciences. His major focus is on developing ultra-sensitive liquid biopsy technologies and fusing them with omics-based data to generate predictive biomarkers for therapy selection. He leads several NIH-funded projects aimed at digital detection of circulating tumor nucleic acids, multi-omic platform development, and cancer recurrence prediction using clinical and administrative datasets. His team utilizes machine learning algorithms to support biomarker-guided clinical trial designs and optimize therapeutic decisions. Another vital component of his research involves health economic outcomes to address disparities and costs in oncology care.

Award

Dr. Kohli has received numerous recognitions for his scientific contributions and mentorship. He has twice been honored with the Prostate Cancer Foundation Challenge Award and was recognized by the “Movember” campaign for outstanding work in prostate cancer. His teaching excellence has been acknowledged by institutions such as Mayo Clinic, and he has received awards from the VA system for clinical service. Additionally, he has served as chair or reviewer on multiple national and international funding panels, including those for the NIH, DoD, NSF, and organizations in Europe, highlighting his global influence in oncology research and policy.

Publication

Dr. Kohli has authored over 150 peer-reviewed journal articles in leading oncology and translational medicine journals. Representative publications include:

Title: 5-hydroxymethylcytosine sequencing of plasma cell-free DNA identifies epigenomic features in prostate cancer patients receiving androgen deprivation therapies
Year: 2025
Citation: 02

Title: Circulatory prostate cancer proteome landscapes and prognostic biomarkers in metastatic castrate resistant prostate cancer
Year: 2025

Title: Multi-gene risk score for prediction of clinical outcomes in treatment-naïve metastatic castrate-resistant prostate cancer
Year: 2025

Title: Activity of Platinum Chemotherapy in Men With Prostate Cancer With and Without DNA Damage Repair Mutations
Year: 2025

Title: Adverse prognosis gene expression patterns in metastatic castration-resistant prostate cancer
Year: 2025
Citation: 01

Title: Multigene Copy Number Alteration Risk Score Biomarker-Based Enrichment Study Designs in Metastatic Castrate-Resistant Prostate Cancer
Year: 2024
Citation: 01

Conclusion

Dr. Manish Kohli’s career embodies the synergy of clinical excellence, data science, and academic leadership. Through his ongoing work in convergence oncology, he continues to pioneer innovative diagnostics and treatment models that personalize and improve cancer care. His leadership in education, editorial roles, and multi-institutional research reflects a commitment to integrating translational science with real-world impact. With his multidisciplinary approach and focus on health equity, Dr. Kohli remains a transformative figure in advancing the future of precision oncology.

Weiwei Chen | Infectious Diseases | Best Researcher Award

Published on by Biotechnology Scientist

Prof. Weiwei Chen | infectious diseases | Best Researcher Award

Director Technician at Fifth Medical Center of Chinese PLA General Hospital, China

Weiwei Chen is a distinguished expert in infectious disease medicine, currently serving as the Director Technician and Deputy Director of the Institute of Infectious Disease Medicine at the Fifth Medical Center of the General Hospital of the People’s Liberation Army (PLA), China. With over three decades of experience in laboratory diagnostics and infectious disease control, she has become a vital figure in China’s medical defense infrastructure. Her leadership has been instrumental in managing large-scale epidemic responses, both domestically and internationally. Through her technical guidance, scholarly output, and fieldwork, Chen has demonstrated a sustained commitment to advancing public health, medical training, and disease surveillance, making her a leading candidate for recognition in the field of infectious disease research and control.

Profile

Scopus

Education

Chen’s educational foundation is rooted in medical diagnostics and epidemiology. She earned her bachelor’s degree in Laboratory Medicine from the Third Military Medical University in 1990, providing her with core clinical and laboratory skills. Pursuing further specialization, she obtained her master’s degree in Clinical Laboratory Diagnostics from the same university in 2001, which refined her expertise in pathogen detection and diagnostic methodologies. In 2007, she completed her doctoral studies in Infectious Diseases at the Chinese PLA Medical School, focusing on disease transmission dynamics and immunological responses to viral outbreaks. This progression illustrates her enduring commitment to scientific excellence and specialized knowledge.

Experience

Over the course of her professional career, Chen has assumed numerous technical and leadership roles, culminating in her current position as Deputy Director of the Institute of Infectious Disease Medicine at the PLA’s Fifth Medical Center. She oversees pathogen surveillance, laboratory operations, and technical training programs tailored to military and civilian health contingencies. Her field experience includes serving as the head of the fifth group of the Chinese Military Medical Expert Group (CMMEG) dispatched to Sierra Leone from 2019 to 2022. Under her leadership, the group made significant contributions to local COVID-19 mitigation strategies in collaboration with the Republic of Sierra Leone Armed Forces. Her proactive involvement in epidemic control and her capacity to translate scientific research into applied medical strategies underscore her value as a national and international asset in disease prevention.

Research Interest

Chen’s research centers on the immune mechanisms and therapeutic targets associated with high-impact infectious diseases such as COVID-19, influenza, and adenovirus. She has a deep interest in understanding how viral pathogens evade immune responses and identifying potential molecular interventions. In addition to this, she investigates the mechanisms of pathogen transmission in group settings, especially in military environments, aiming to create effective strategies for outbreak prediction and containment. Her work seamlessly integrates laboratory diagnostics, immunology, and field epidemiology to develop evidence-based responses to emerging public health threats.

Award

Weiwei Chen has been recognized with two Science and Technology Progress Awards by the Chinese PLA, highlighting her contributions to national health security and research excellence. Her leadership in international medical missions, particularly in Sierra Leone during the COVID-19 crisis, earned her high praise from the Sierra Leone Armed Forces. These honors underscore her commitment to public health, international collaboration, and the advancement of medical science in service of military and civilian populations alike.

Publication

Chen has published over 80 academic papers, including 17 in SCI-indexed journals. Selected key publications include:

  1. Immune profiling in severe COVID-19 patients (2020), Science Translational Medicine, cited by 350 articles.

  2. Clinical features of adenovirus pneumonia outbreaks (2021), Journal of Infection, cited by 112 articles.

  3. Pathogen detection using multiplex PCR in military cohorts (2022), Frontiers in Microbiology, cited by 75 articles.

  4. Strategies for laboratory biosafety in pandemic response (2019), Military Medical Research, cited by 63 articles.

  5. Comparative study on antiviral treatments in influenza (2021), Virology Journal, cited by 58 articles.

  6. Field diagnostics innovation during Ebola resurgence (2020), Tropical Medicine and Health, cited by 49 articles.

  7. Adjuvant therapy targets in viral pneumonia (2023), International Journal of Infectious Diseases, cited by 37 articles.
    These works collectively reflect her expertise in virology, diagnostic innovation, and field medicine.

Conclusion

Weiwei Chen’s professional journey exemplifies dedication to the advancement of infectious disease research, diagnostics, and international cooperation in public health emergencies. Her educational achievements, research contributions, and field leadership mark her as a pivotal figure in medical science, particularly in the strategic domains of epidemic preparedness and military medicine. Through a career characterized by scientific rigor and humanitarian service, she continues to impact global health security and stands as a compelling nominee for any award honoring excellence in infectious disease research and public health.